FY2017 EPS Estimates for VolitionRX Ltd (VNRX) Reduced by Zacks Investment Research
VolitionRX Ltd (NYSEAMERICAN:VNRX) – Zacks Investment Research lowered their FY2017 earnings per share (EPS) estimates for VolitionRX in a research report issued on Wednesday. Zacks Investment Research analyst B. Marckx now expects that the medical research company will post earnings per share of ($0.56) for the year, down from their prior forecast of ($0.55). Zacks Investment Research also issued estimates for VolitionRX’s Q4 2017 earnings at ($0.16) EPS, FY2018 earnings at ($0.51) EPS and FY2019 earnings at ($0.41) EPS.
Separately, HC Wainwright set a $10.00 target price on shares of VolitionRX and gave the company a “buy” rating in a research report on Friday, August 11th.
Shares of VolitionRX (NYSEAMERICAN VNRX) opened at $3.23 on Monday. VolitionRX has a 1 year low of $2.08 and a 1 year high of $5.45.
A number of large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in VolitionRX by 177.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,376 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 19,414 shares during the last quarter. Leisure Capital Management bought a new position in VolitionRX during the 3rd quarter valued at about $193,000. Finally, Lagoda Investment Management L.P. grew its holdings in VolitionRX by 6.4% during the 3rd quarter. Lagoda Investment Management L.P. now owns 3,356,754 shares of the medical research company’s stock valued at $8,828,000 after purchasing an additional 201,062 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for VolitionRX Ltd (VNRX) Reduced by Zacks Investment Research” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/fy2017-eps-estimates-for-volitionrx-ltd-vnrx-reduced-by-zacks-investment-research/1728100.html.
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.